Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

Novo Nordisk reported 22% growth in its obesity care business in Q1 2026, while Eli Lilly's Mounjaro and Zepbound sales rose 125% and 80%, respectively, underscoring Lilly's current lead in GLP-1 drugs. The article argues Novo is more attractive on valuation and income, citing a roughly 4% dividend yield and about 10x P/E versus Eli Lilly's 0.65% yield and 37x P/E. Novo has also warned 2026 will be a difficult year, but early adoption of its Wegovy pill could support longer-term volume growth.

Analysis

The market is implicitly pricing this as a winner-take-most GLP-1 duopoly, but the more interesting second-order effect is that the category is still expanding faster than share is shifting. If the oral form lowers the barrier for needle-averse patients, Novo can still participate in net new demand even if it never regains the same share as Lilly in injectables. That matters because the equity debate is no longer about who owns the entire market; it is about whether both firms can monetize a much larger TAM while the channel mix changes.

Novo’s setup is a classic “bad narrative, decent fundamentals” gap. A depressed multiple with a 4% yield and moderate payout gives management optionality: they can absorb a soft 2026 through margin pressure and still defend capital returns while the pill builds an installed base. The risk is that investors anchor on the next two quarters of pricing and volume optics, but the stock could rerate quickly if oral adoption proves incremental rather than cannibalistic, especially if compounding-related leakage continues to fade.

The main counterpoint to the bullish Novo case is execution asymmetry. Lilly’s current operating momentum gives it more room to reinvest, accelerate supply, and price selectively without needing a valuation rerating to fund growth. So the cleaner trade is not a naked long/short on product superiority, but a valuation-and-duration spread: own the under-earning balance-sheet return story and hedge the premium multiple. If Novo’s 2026 warning becomes less severe by mid-year, this could work as a 6-12 month mean reversion trade rather than a secular conviction call.

Key Decisions for Investors

• Go long NVO on weakness, targeting a 6-12 month re-rating toward low-teens P/E if oral uptake continues to broaden the market; use the 4% yield as carry while waiting. Risk: another supply/pricing disappointment can keep the multiple compressed.
• Pair trade: long NVO / short LLY in roughly dollar-neutral size for a 6-9 month horizon. The thesis is valuation convergence if market share stabilizes and Lilly’s premium multiple starts to reflect perfection risk rather than inevitability.
• For conservative accounts, sell cash-secured puts on NVO 10-15% below spot into any post-warning selloff. This expresses willingness to own the dividend while improving entry price; downside is assignment into a still-messy 2026 guide.
• Avoid initiating fresh LLY longs here unless on a 10-15% drawdown. The setup is still fundamentally strong, but the risk/reward is poor because the stock already discounts sustained category dominance and leaves little room for execution slippage.
• If you want asymmetric upside on the Novo catch-up story, use 9-12 month call spreads on NVO rather than stock. That limits exposure if 2026 guidance deterioration lasts longer than expected, while preserving upside on any evidence of oral adoption inflecting.